A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
|Articles|March 5, 2006
- Applied Clinical Trials-03-05-2006
- Volume 0
- Issue 0
Welcome
Welcome to the Applied Clinical Trials eShow Daily coming from the floor of the DIA 18th Annual EuroMeeting in Paris, France.
Advertisement
Welcome to the Applied Clinical Trials eShow Daily coming from the floor of the DIA 18th Annual EuroMeeting
in Paris, France.
Watch your email box for digests of the meetings most important and pertinent clinical news-gathered from sessions, press briefings and the exhibit hall.
Whether you are live at the 2006 DIA EuroMeeting this week or you are elsewhere, we hope you benefit from our daily coverage.
Do you have colleagues
and associates who
are not receiving
Applied Clinical Trials
E-Show Daily?
Have them log on to
for the latest updates
from DIA.
Thank you, Toby J. Hindin, Editor-in-Chief.
Articles in this issue
over 20 years ago
Program InformationAdvertisement
Related to this article
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
4
What "Patient Voice" Actually Requires: Beyond the Buzzword
5